Pathways to the elimination of hepatitis C: prioritising access for all

Expert Rev Clin Pharmacol. 2017 Oct;10(10):1023-1026. doi: 10.1080/17512433.2017.1383894.

Authors

Alisa E Pedrana^{1

2}, Rachel Sacks-Davis^{1

3}, Joseph S Doyle^{1

4}, Margaret E Hellard^{1

4}

Affiliations

¹ a Disease Elimination Program , Burnet Institute , Melbourne , Australia.
² b Department of Epidemiology and Preventive Medicine , Monash University , Melbourne , Australia.
³ c Department of Medicine , The University of Melbourne , Melbourne , Australia.
⁴ d Department of Infectious Diseases , The Alfred and Monash University , Melbourne , Australia.

PMID: 28942660
DOI: 10.1080/17512433.2017.1383894

No abstract available

Keywords: Cost-effectiveness; IDU; disease elimination; hepatitis C virus; implementation science; models of care; testing.

Publication types

Editorial

MeSH terms

Antiviral Agents / administration & dosage*
Antiviral Agents / economics
Cost-Benefit Analysis
Disease Eradication
Health Services Accessibility*
Hepatitis C / drug therapy*
Humans

Substances

Antiviral Agents